vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and NewtekOne, Inc. (NEWT). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $73.3M, roughly 1.2× NewtekOne, Inc.). NewtekOne, Inc. runs the higher net margin — 111.8% vs 22.8%, a 89.0% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -2.7%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-579.3M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 12.2%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

FDMT vs NEWT — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.2× larger
FDMT
$85.1M
$73.3M
NEWT
Growing faster (revenue YoY)
FDMT
FDMT
+8508902.7% gap
FDMT
8508900.0%
-2.7%
NEWT
Higher net margin
NEWT
NEWT
89.0% more per $
NEWT
111.8%
22.8%
FDMT
More free cash flow
FDMT
FDMT
$607.8M more FCF
FDMT
$28.5M
$-579.3M
NEWT
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
12.2%
NEWT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FDMT
FDMT
NEWT
NEWT
Revenue
$85.1M
$73.3M
Net Profit
$19.4M
$19.5M
Gross Margin
Operating Margin
17.3%
Net Margin
22.8%
111.8%
Revenue YoY
8508900.0%
-2.7%
Net Profit YoY
139.1%
6.6%
EPS (diluted)
$0.43
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
NEWT
NEWT
Q4 25
$85.1M
$73.3M
Q3 25
$90.0K
$74.9M
Q2 25
$15.0K
$70.2M
Q1 25
$14.0K
$66.3M
Q4 24
$1.0K
$75.4M
Q3 24
$3.0K
$62.8M
Q2 24
$5.0K
$61.1M
Q1 24
$28.0K
$58.3M
Net Profit
FDMT
FDMT
NEWT
NEWT
Q4 25
$19.4M
$19.5M
Q3 25
$-56.9M
$17.9M
Q2 25
$-54.7M
$13.7M
Q1 25
$-48.0M
$9.4M
Q4 24
$18.3M
Q3 24
$-43.8M
$11.9M
Q2 24
$-35.0M
$10.9M
Q1 24
$-32.4M
$9.7M
Operating Margin
FDMT
FDMT
NEWT
NEWT
Q4 25
17.3%
Q3 25
-67983.3%
Q2 25
-396373.3%
Q1 25
-383007.1%
Q4 24
Q3 24
-1704400.0%
Q2 24
-849120.0%
Q1 24
-136200.0%
Net Margin
FDMT
FDMT
NEWT
NEWT
Q4 25
22.8%
111.8%
Q3 25
-63195.6%
23.9%
Q2 25
-364386.7%
19.5%
Q1 25
-342657.1%
14.1%
Q4 24
24.3%
Q3 24
-1461433.3%
19.0%
Q2 24
-699060.0%
17.9%
Q1 24
-115717.9%
16.6%
EPS (diluted)
FDMT
FDMT
NEWT
NEWT
Q4 25
$0.43
$0.64
Q3 25
$-1.01
$0.67
Q2 25
$-0.98
$0.52
Q1 25
$-0.86
$0.35
Q4 24
$0.70
Q3 24
$-0.79
$0.45
Q2 24
$-0.63
$0.43
Q1 24
$-0.66
$0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
NEWT
NEWT
Cash + ST InvestmentsLiquidity on hand
$402.7M
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$505.7M
$397.6M
Total Assets
$566.7M
$2.7B
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
NEWT
NEWT
Q4 25
$402.7M
Q3 25
$305.1M
Q2 25
$293.2M
Q1 25
$321.4M
Q4 24
$424.9M
Q3 24
$501.9M
Q2 24
$541.9M
Q1 24
$525.9M
Total Debt
FDMT
FDMT
NEWT
NEWT
Q4 25
$819.9M
Q3 25
$748.5M
Q2 25
$657.3M
Q1 25
$774.0M
Q4 24
$708.0M
Q3 24
$655.8M
Q2 24
$652.0M
Q1 24
$662.5M
Stockholders' Equity
FDMT
FDMT
NEWT
NEWT
Q4 25
$505.7M
$397.6M
Q3 25
$369.0M
$386.7M
Q2 25
$420.9M
$312.2M
Q1 25
$469.7M
$302.3M
Q4 24
$510.6M
$296.3M
Q3 24
$552.9M
$281.8M
Q2 24
$588.3M
$274.0M
Q1 24
$600.6M
$254.1M
Total Assets
FDMT
FDMT
NEWT
NEWT
Q4 25
$566.7M
$2.7B
Q3 25
$424.0M
$2.4B
Q2 25
$473.6M
$2.1B
Q1 25
$515.7M
$2.1B
Q4 24
$560.4M
$2.1B
Q3 24
$604.0M
$1.7B
Q2 24
$620.1M
$1.6B
Q1 24
$629.9M
$1.5B
Debt / Equity
FDMT
FDMT
NEWT
NEWT
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
Q2 24
2.38×
Q1 24
2.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
NEWT
NEWT
Operating Cash FlowLast quarter
$28.6M
$-579.2M
Free Cash FlowOCF − Capex
$28.5M
$-579.3M
FCF MarginFCF / Revenue
33.5%
-790.0%
Capex IntensityCapex / Revenue
0.1%
0.1%
Cash ConversionOCF / Net Profit
1.47×
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
NEWT
NEWT
Q4 25
$28.6M
$-579.2M
Q3 25
$-46.5M
$-167.3M
Q2 25
$-43.4M
$-199.8M
Q1 25
$-47.8M
$-60.7M
Q4 24
$-134.6M
$-153.0M
Q3 24
$-29.4M
$-25.7M
Q2 24
$-30.2M
$2.9M
Q1 24
$-29.1M
$-38.7M
Free Cash Flow
FDMT
FDMT
NEWT
NEWT
Q4 25
$28.5M
$-579.3M
Q3 25
$-46.6M
$-167.3M
Q2 25
$-43.4M
$-199.9M
Q1 25
$-48.4M
$-60.7M
Q4 24
$-138.4M
$-153.5M
Q3 24
$-31.2M
$-25.9M
Q2 24
$-30.6M
$2.9M
Q1 24
$-29.8M
$-38.7M
FCF Margin
FDMT
FDMT
NEWT
NEWT
Q4 25
33.5%
-790.0%
Q3 25
-51765.6%
-223.3%
Q2 25
-289620.0%
-284.7%
Q1 25
-345635.7%
-91.6%
Q4 24
-13837100.0%
-203.6%
Q3 24
-1038966.7%
-41.2%
Q2 24
-611840.0%
4.7%
Q1 24
-106421.4%
-66.5%
Capex Intensity
FDMT
FDMT
NEWT
NEWT
Q4 25
0.1%
0.1%
Q3 25
101.1%
0.0%
Q2 25
440.0%
0.1%
Q1 25
4507.1%
0.1%
Q4 24
378600.0%
0.6%
Q3 24
59266.7%
0.4%
Q2 24
6980.0%
0.1%
Q1 24
2535.7%
0.1%
Cash Conversion
FDMT
FDMT
NEWT
NEWT
Q4 25
1.47×
-29.64×
Q3 25
-9.35×
Q2 25
-14.58×
Q1 25
-6.48×
Q4 24
-8.35×
Q3 24
-2.15×
Q2 24
0.27×
Q1 24
-4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons